Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

These two biotechs could ride the wave of significant clinical progress. However, both carry above-average risk.

• Abivax stock is taking a hit today. Why is ABVX stock falling?

Abivax CEO Marc de Garidel told CNBC that the terms of any future deal will be better after it releases data on a key trial in the second quarter. Intense takeover rumors have surrounded the French biotech company for months, with analysts seeing it as a prime takeover target.

Abivax is viewed as a buyout candidate thanks to its promising lead drug candidate, obefazimod. Abivax is testing obefazimod for multiple conditions.

The Fund rebounded and outperformed the Russell 2000 ® Growth Index in the fourth quarter. Boot Barn's revenues and earnings handily exceeded estimates, with greater transaction volumes and new store openings. Abivax reported strong clinical trial results for its obefazimod treatment to address ulcerative colitis in a longer lasting manner.

Abivax remains a 'Strong Buy' due to obefazimod's positive phase 3 UC data and upcoming pivotal maintenance results in late Q2 2026. Company's differentiated mir-124 enhancer mechanism targets both inflammatory and fibrotic pathways, positioning it uniquely in the IBD therapeutic landscape. Key catalysts include 44-week phase 3 UC maintenance data and phase 2b Crohn's Disease induction results, both expected in 2026.

Biotechnology ‌company Abivax dismissed information published ​by ​French media publication "La ⁠Lettre" saying ​it had ​granted AstraZeneca exclusive access to ​confidential ​information until March 23 ‌to ⁠allow the British pharmaceutical giant ​to ​formalise ⁠a takeover ​offer.